Generic Medicine Info
Indications and Dosage
Type 2 diabetes mellitus
Adult: Initially, 15 mg as a single daily dose, adjust by increments of 15 mg to a usual dose of 45-60 mg daily in 2 or 3 unequally divided doses, the largest dose being taken in the morning. Up to 60 mg/dose and 180 mg/day.
Should be taken with food. Small doses may be taken up to 30 min before breakfast. Large doses must be taken w/ meals.
Type 1 diabetes mellitus; ketoacidosis; severe infection; trauma; other severe conditions where gliquidone is unlikely to control hyperglycaemia; pregnancy; lactation; porphyria; hypersensitivity; diabetic coma and pre-coma; prediabetic states; severe hepatic or renal impairment.
Special Precautions
Elderly, debilitated or malnourished patients; adrenal or pituitary insufficiency. Monitor blood glucose concentrations carefully.
Adverse Reactions
GI disturbances; metallic taste; skin rashes, pruritus, photosensitivity; facial flushing; hypoglycaemia; syndrome of inappropriate secretion of antidiuretic hormone; cholestatic jaundice; Stevens-Johnson syndrome; exfoliative dermatitis; erythema nodosum; increased appetite; wt gain; blood disorders.
Drug Interactions
Increased hypoglycaemic effect by ACE inhibitors, alcohol, allopurinol, some analgesics, azole antifungals, cimetidine, clofibrate and related compounds, coumarin anticoagulants, halofenate, heparin, octreotide, ranitidine, sulfinpyrazone, sulfonamides, tricyclic antidepressants, thyroid hormones, MAOIs, chloramphenicol, tetracyclines. β-blockers increase hypoglycaemia and may mask warning signs. Diminished hypoglycaemic effect by adrenaline, aminoglutethimide, diazoxide, rifamycins, chlorpromazine, corticosteroids, oral contraceptives, hormones, thiazide diuretics.
Lab Interference
Altered liver enzyme values.
Description: Gliquidone stimulates the production of organic insulin and normalizes the altered metabolic situation when diet alone cannot regulate this satisfactorily.
MIMS Class
Antidiabetic Agents
Disclaimer: This information is independently developed by MIMS based on Gliquidone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in